CEDAR KNOLLS, NJ--(Marketwired - Jan 22, 2015) - MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin™ exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle.

Robert Ashton, M.D., Chief Medical Officer of MYOS, commented, "We believe the findings from our mechanism of action preclinical study are extremely important observations which will strengthen our ability to build a compelling scientific and clinical rationale for deploying Fortetropin in a number of significant clinical indications including cachexia, sarcopenia, anorexia nervosa and obesity. Based on this study, we believe Fortetropin may be involved in three crucial regulatory pathways responsible for healthy muscle growth."

Myostatin is a naturally occurring regulatory protein which prevents muscle growth. Myostatin serum levels increase as people age which can lead to age-related muscle loss or sarcopenia. Fortetropin's ability to reduce serum myostatin levels has been clinically proven. Regulation of myostatin may be a key element in the treatment of sarcopenia.

In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation.

Finally, the Company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.

Dr. Ashton concluded, "We believe these observations have the potential to significantly impact clinical appreciation of Fortetropin's broad biotherapeutic activity in many important muscle disorders, as a tool in age-management as well as for patients experiencing muscle degeneration caused by chronic diseases."

About MYOS CorporationMYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

The Company's first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking StatementsAny statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, including the studies described herein, customer demand for our products, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully develop and launch our own core branded products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to enter into strategic relationships with new distributors, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.